LEADER 03183nam  2200553   450 
001 9910786408003321
005 20230801233131.0
010   $a88-97419-38-0
035   $a(CKB)3710000000118109
035   $a(EBL)3034683
035   $a(SSID)ssj0001399525
035   $a(PQKBManifestationID)11820535
035   $a(PQKBTitleCode)TC0001399525
035   $a(PQKBWorkID)11458804
035   $a(PQKB)11621819
035   $a(MiAaPQ)EBC3034683
035   $a(Au-PeEL)EBL3034683
035   $a(CaPaEBR)ebr10960569
035   $a(OCoLC)881727882
035   $a(EXLCZ)993710000000118109
100   $a20141106d2012      uy|            0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt
182   $cc
183   $acr
200 10$aPharmacoeconomics $eprinciples and practice /$fLorenzo Pradelli, Albert Wertheimer
205   $aFirst edition.
210  1$aTorino, Italy :$cSEEd,$d2012.
215   $a1 online resource (125 p.)
300   $aDescription based upon print version of record.
311   $a88-97419-37-2 
320   $aIncludes bibliographical references.
327   $a""Title Page""; ""Colophon ""; ""Table of Contents""; ""Preface""; ""Introduction""; ""Health Care Dilemma""; ""Opportunity Cost""; ""Efficiency and Equity""; ""Pharmacoeconomics""; ""Sensitivity Analysis""; ""Summary""; ""Further Readings""; ""1 Definitions and Basic Concepts""; ""1.1 Definitions""; ""1.2 Costs""; ""1.3 Consequences""; ""1.4 Perspectives""; ""1.5 Time Horizon""; ""2 Pharmacoeconomic Evaluations""; ""2.1 Introduction""; ""2.2 Cost Analysis""; ""2.3 Cost-outcomes Analysis""; ""2.4 Utility""; ""2.5 Psychometrics""; ""3 Modeling Frameworks""; ""3.1 Steps in Decision Analysis""
327   $a""3.2 Influence Diagrams""""3.3 Markov Models""; ""3.4 Discrete-event Simulation""; ""3.5 Agent-based Models""; ""4 Budget Impact Analysis""; ""4.1 Introduction""; ""4.2 Example: Budget Impact Analysis of Clinical Guidelines in COPD Patients""; ""5 Patient Reported Outcomes""; ""5.1 Introduction""; ""5.2 From Biological Measures to Patient Reported Outcome""; ""5.3 Quality of Life, Health Related Quality of Life, and Patient Reported Outcomes""; ""5.4 PRO Dimensions""; ""5.5 Every Patient has Individual Health Perceptions""; ""5.6 Applications of PRO Instruments""
327   $a""5.7 Identifying an Appropriate Instrument for Measuring PRO""""5.8 PRO Instruments""; ""5.9 When are the Results of PROs Relevant?""; ""5.10 Summary and Conclusion""; ""6 Data Sources and Accounting for Uncertainty""; ""6.1 Data Sources""; ""6.2 Statistical Analysis""; ""6.3 Accounting for Uncertainty""; ""6.4 Pharmacoeconomic Studies""; ""6.5 Conclusions: Evaluating Pharmacoeconomic Studies""; ""References""; ""Glossary""; ""Authors""
606   $aDrugs$xCost effectiveness
606   $aPharmacy$xEconomic aspects
615  0$aDrugs$xCost effectiveness.
615  0$aPharmacy$xEconomic aspects.
700   $aPradelli$b Lorenzo$01483693
702   $aWertheimer$b Albert
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910786408003321
996   $aPharmacoeconomics$93701967
997   $aUNINA